Author

U. Pagotto

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Case report Open access Sep 2026

Case Report: Reopening the anabolic window — romosozumab added to ongoing denosumab for severe osteoporosis in two kidney transplant recipients

Kidney transplant recipients develop disorders of mineral and bone metabolism that further impair bone strength, leading to osteoporosis and a high fracture risk. However, evidence in this setting is limited. Romosozumab, a sclerostin inhibitor with both anabolic and antiresorptive effects, is an attractive option, but...

Simona Barbuto, Paolo Mastromauro, G. Zavatta et al. · Frontiers in Endocrinology · 0 citations

Open access Aug 2026

Longitudinal changes in cardiorenal risk scores after SGLT2 inhibitor initiation in patients with CKD with and without type 2 diabetes.

BACKGROUND Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have become the standard of care in managing chronic kidney disease (CKD) and heart failure (HF), both in patients with and without type 2 diabetes mellitus (T2DM). Nonetheless, identifying those at persistent high cardiovascular (CV) and renal risk remains...

I. Capelli, D. Vetrano, D. Ribichini et al. · JN. Journal of Nephrology (M... · 0 citations

Open access Aug 2026

AD18 Integrated steroidomic and untargeted metabolomic profiling reveals distinct circulating signatures of adrenocortical carcinoma

Adrenal tumours display marked biological heterogeneity, making the distinction between benign and malignant lesions challenging. Liquid chromatography–high-resolution mass spectrometry (LC-HRMS) enables simultaneous investigation of steroidomic and broader metabolomic alterations. To identify integrated c...

G. Galante, T. Sénard, A. Gennai et al. · European Journal of Endocrin... · 0 citations